SMi proudly present their 2nd annual conference on Allergies, taking place on 8th & 9th July 2015 in London, UK. Allergies 2015 will focus on developments of novel vaccines and adjuvants for immunotherapy, along with a strong focus on allergy clinical trials and pharmacovigilance to gain a solid understanding of the current requirements and obligations in the development of immunotherapy products.
The conference will highlight increasing patient compliance and increasing quality of life for patients that are being treated on a day to day basis through new mechanisms of delivery. There is also a emphasis on personalised medicines for the treatment of specific phenotypes rather than taking the one fits all strategy and new pathways for pioneering targeting strategies to be developed.
5 Reasons Why You Should Attend:
• Discovering novel strategies being implemented in the field of vaccines and adjuvants for immunotherapy
• Overcoming challenges faced in the development of clinical trials for allergen therapeutics including trial policies and paediatrics
• Creating new solutions for the delivery of therapeutics to increase patient quality of life and increase compliance to provide an optimal treatment strategy
• Highlighting new pathways involved in the development of allergy to provide a better understanding of new targets for drug development and targeting
• Reviewing new developments in the field of allergy immunotherapeutics to provide an insight into future development prospects.
Key Speakers Include:
• Tim Higenbottam, Research & Development Director, Allergy Therapeutics
• Rod Hafner, Senior Vice President R&D, Circassia
• Diderik Boot, Medical Director, HAL Allergies
• Pierre-Henri Benhamou, CEO, DBV Technologies
• Juan Gispert, Senior Medical Director, European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles
• Tracy Hussell, Principal Investigator, University of Manchester, Haemostatix
The conference will highlight increasing patient compliance and increasing quality of life for patients that are being treated on a day to day basis through new mechanisms of delivery. There is also a emphasis on personalised medicines for the treatment of specific phenotypes rather than taking the one fits all strategy and new pathways for pioneering targeting strategies to be developed.
5 Reasons Why You Should Attend:
• Discovering novel strategies being implemented in the field of vaccines and adjuvants for immunotherapy
• Overcoming challenges faced in the development of clinical trials for allergen therapeutics including trial policies and paediatrics
• Creating new solutions for the delivery of therapeutics to increase patient quality of life and increase compliance to provide an optimal treatment strategy
• Highlighting new pathways involved in the development of allergy to provide a better understanding of new targets for drug development and targeting
• Reviewing new developments in the field of allergy immunotherapeutics to provide an insight into future development prospects.
Key Speakers Include:
• Tim Higenbottam, Research & Development Director, Allergy Therapeutics
• Rod Hafner, Senior Vice President R&D, Circassia
• Diderik Boot, Medical Director, HAL Allergies
• Pierre-Henri Benhamou, CEO, DBV Technologies
• Juan Gispert, Senior Medical Director, European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles
• Tracy Hussell, Principal Investigator, University of Manchester, Haemostatix
